Involvement of the Costimulatory Molecules ICOS and OX40 in Neuromyelitis Optica Spectrum Disorder

Gene Expression Signatures Associated with Prior Rituximab Treatment in Patients with Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the CHAMPION-NMOSD Trial

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Relapse Risk in a Contemporary, Population-based Cohort

Author:Langer-Gould, Annette   Scott, Jason   Torres, Fernando   Smith, Jessica   

Session Name:S6: Autoimmune Neurology: NMOSD and MOGAD  

Topic:Multiple Sclerosis  

Program Number:S6.008  

Author Institution:

Real-world Clinical Outcomes with Eculizumab and Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Global NMO SPOTLIGHT Registry